Vericel Corporation (NASDAQ: VCEL) saw its stock price surge 13% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The biotechnology company significantly outperformed market expectations, demonstrating strong growth and improved profitability across key metrics.

The Q3 earnings report revealed several positive highlights. Vericel reported revenue of $67.5 million, handily beating the analyst estimate of $64.6 million. Earnings per share (EPS) came in at $0.10, surpassing the anticipated loss of $0.01 per share. The company's flagship product, MACI, saw its revenue grow by 25% to $55.7 million, driving overall growth. Profitability also improved significantly, with adjusted EBITDA reaching $17 million, representing a 25% margin.

Adding to the optimistic sentiment, Vericel provided a favorable full-year revenue outlook of $272-276 million, aligning well with current market estimates. The company also reaffirmed its expectations for MACI revenue growth in the low 20% range and maintained its gross margin guidance at 74%. With these strong results and positive future guidance, investors are showing confidence in Vericel's growth strategy and market position, driving the significant pre-market stock price increase.